Cargando…

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview

Stereotactic body radiotherapy (SBRT), a type of external beam radiotherapy, yields local control of hepatocellular carcinoma (HCC) at rates as high as 90%. SBRT has been recognized as an alternative therapy for patients for whom standard modalities such as surgery (resection or transplantation) or...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsuo, Yukinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956001/
https://www.ncbi.nlm.nih.gov/pubmed/36826151
http://dx.doi.org/10.3390/curroncol30020190
_version_ 1784894485535129600
author Matsuo, Yukinori
author_facet Matsuo, Yukinori
author_sort Matsuo, Yukinori
collection PubMed
description Stereotactic body radiotherapy (SBRT), a type of external beam radiotherapy, yields local control of hepatocellular carcinoma (HCC) at rates as high as 90%. SBRT has been recognized as an alternative therapy for patients for whom standard modalities such as surgery (resection or transplantation) or ablation are deemed unsuitable. SBRT has the potential to improve the prognosis of HCC, as it can be used as an adjunct to other treatment modalities. The assessment of post-SBRT images of the treated tumor and surrounding normal liver tissue requires special attention. Future research is warranted to determine how best to use SBRT versus other therapies and how to combine them.
format Online
Article
Text
id pubmed-9956001
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99560012023-02-25 Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview Matsuo, Yukinori Curr Oncol Opinion Stereotactic body radiotherapy (SBRT), a type of external beam radiotherapy, yields local control of hepatocellular carcinoma (HCC) at rates as high as 90%. SBRT has been recognized as an alternative therapy for patients for whom standard modalities such as surgery (resection or transplantation) or ablation are deemed unsuitable. SBRT has the potential to improve the prognosis of HCC, as it can be used as an adjunct to other treatment modalities. The assessment of post-SBRT images of the treated tumor and surrounding normal liver tissue requires special attention. Future research is warranted to determine how best to use SBRT versus other therapies and how to combine them. MDPI 2023-02-18 /pmc/articles/PMC9956001/ /pubmed/36826151 http://dx.doi.org/10.3390/curroncol30020190 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Matsuo, Yukinori
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title_full Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title_fullStr Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title_full_unstemmed Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title_short Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
title_sort stereotactic body radiotherapy for hepatocellular carcinoma: a brief overview
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956001/
https://www.ncbi.nlm.nih.gov/pubmed/36826151
http://dx.doi.org/10.3390/curroncol30020190
work_keys_str_mv AT matsuoyukinori stereotacticbodyradiotherapyforhepatocellularcarcinomaabriefoverview